Please use this identifier to cite or link to this item:
Title: Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore
Authors: Lee, V.J.
Kai, H.P. 
Chen, M.I.
Chow, A.
Ma, S.
Kee, T.G.
Yee, S.L.
Issue Date: Jan-2006
Citation: Lee, V.J., Kai, H.P., Chen, M.I., Chow, A., Ma, S., Kee, T.G., Yee, S.L. (2006-01). Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerging Infectious Diseases 12 (1) : 95-102. ScholarBank@NUS Repository.
Abstract: We compared strategies for stockpiling neuraminidase inhibitors to treat and prevent influenza in Singapore. Costbenefit and cost-effectiveness analyses, with Monte Carlo simulations, were used to determine economic outcomes. A pandemic in a population of 4.2 million would result in an estimated 525-1,775 deaths, 10,700-38,600 hospitalization days, and economic costs of $0.7 to $2.2 billion Singapore dollars. The treatment-only strategy had optimal economic benefits: stockpiles of antiviral agents for 40% of the population would save an estimated 418 lives and $414 million, at a cost of $52.6 million per shelf-life cycle of the stockpile. Prophylaxis was economically beneficial in high-risk subpopulations, which account for 78% of deaths, and in pandemics in which the death rate was >0.6%. Prophylaxis for pandemics with a 5% case-fatality rate would save 50,000 lives and $81 billion. These models can help policymakers weigh the options for pandemic planning .
Source Title: Emerging Infectious Diseases
ISSN: 10806040
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on May 12, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.